Steven Mah
Stock Analyst at TD Cowen
(2.23)
# 2,643
Out of 5,182 analysts
29
Total ratings
37.93%
Success rate
11.08%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $61.88 | -6.27% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $22.19 | +39.70% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $7.98 | +1,403.76% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $3.69 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $12.80 | +228.13% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $3.91 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.55 | +545.16% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $3.95 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.62 | +701.53% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $207.74 | -25.39% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $16.18 | +765.27% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.74 | +2,888.51% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $132.86 | +212.36% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $12.89 | +1,839.49% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $61.88
Upside: -6.27%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $22.19
Upside: +39.70%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $7.98
Upside: +1,403.76%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $3.69
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $12.80
Upside: +228.13%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.91
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.55
Upside: +545.16%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.95
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.62
Upside: +701.53%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $207.74
Upside: -25.39%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $16.18
Upside: +765.27%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.74
Upside: +2,888.51%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $132.86
Upside: +212.36%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $12.89
Upside: +1,839.49%